Catherine Boule
Managing Partner @ Karista
Paris, France
Catherine Boule is a seed investor at Karista in Paris focused on Health Care and Biotechnology. Catherine Boule - Managing Partner @ Karista
- Total investments:
- 20
- Last investment:
- Lead investor:
- 15%
Last updated:
For AI agents: llms.txt
Industries Catherine Boule invests in
Health CareBiotechnologyMedicalMedical DeviceTherapeutics
Stages Catherine Boule invests in
SeedSeries AVenture - Series UnknownSeries BSeries C
Countries Catherine Boule invests in
France
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 7 (35%)
- Biotechnology 7 (35%)
- Medical 6 (30%)
- Medical Device 5 (25%)
- Therapeutics 3 (15%)
Stage
- Seed 10 (50%)
- Series A 3 (15%)
- Venture - Series Unknown 2 (10%)
- Series B 1 (5%)
- Series C 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects. | $16M / Venture - Series Unknown / Sep 22, 2026 | ||
| Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects. | $27.1M / Venture - Series Unknown / Sep 19, 2022 | ||
| Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life. | $4.4M / Seed / Jul 04, 2022 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $7.7M / Series B / Nov 06, 2019 | ||
| Healthcare professionals are now overwhelmed by the volume of patients and images. They need new tools. As safeguards of our Healthcare system, they need to be empowered and to participate in the AI production process. This is our mission through our co-creation projects. | $6.2M / Seed / Sep 24, 2019 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $17.6M / Series B / Oct 17, 2018 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $2.1M / Series A / Jan 04, 2018 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | Seed / Feb 07, 2017 | ||
| Acticor Biotech is a biopharmaceutical company developing an innovative drug for the treatment in the acute phase of ischemic stroke. Acticor Biotech’s project stems from the sheer need for new therapeutic options to manage stroke. According to the World Health Organization, 15 million people suffer stroke worldwide each year. Of these, 5 milliondies and another 5 million are permanently disabled. Stroke is the third cause of death in the world and the leading cause of death among women. It is also the first cause of adult acquired disabilities resulting from the neurological damages sustained by 75% of the survivors. However, only one treatment is presently recommended by health authorities and is it estimated that only 15% of ischemic stroke patients are treated with it, with less than 40% efficacy. So while this treatment is very useful for ischemic stroke, a major need for a new treatment capable of effectively treating a majority of ischemic stroke patients remains.Acticor Biotech was founded in November 2013 and is headquartered in Paris, France. | $1.6M / Venture - Series Unknown / Feb 07, 2017 | ||
| TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation. | Seed / Sep 01, 2015 | ||
| See all 20 investments → | |||
Co-Investors
About Karista
Karista is an early-stage venture capital firm created in 2001. We funded 90+ companies over the past two decades and support tomorrow’s game changers in the field of Health, Digital, Tech, and NewSpace. We have always worked to provide more than cash and partnered with entrepreneurs whom we share a common vision with.
Karista Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Agathe Testu
Secretary General - RCCI
|
|||
Baudouin Hue
Partner
|
|||
Benjamin Zerbib
Investment Director
|
|||
|
Catherine Boule
Managing Partner
|
|||
Elodie Feraille
Management Assistant
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
Health Care Investors
48,627 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Medical Investors
21,234 investors
Medical Device Investors
12,432 investors
Health Care VC Funds
36,465 investors
Biotech VC Funds
20,850 investors
Biotechnology VC Funds
18,763 investors
Medical VC Funds
18,263 investors
FAQ
What does Catherine Boule invest in?
Catherine Boule invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 20 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Catherine Boule?
Public channels for Catherine Boule include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Catherine Boule last invest?
The most recent investment recorded for Catherine Boule closed in Sep 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
